Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab

Teresa Marta Cardesa-Salzmann; Bernhard Stephan; Arne Simon; Rhoikos Furtwängler; Dominik Schöndorf; Sabine Heine; Eyad Torfah; Margaux Lux; Sonja Meyer; Norbert Graf

doi:10.1002/ccr3.5902

Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab

Clin Case Rep. 2022 May 20;10(5):e05902. doi: 10.1002/ccr3.5902. eCollection 2022 May.

Affiliations

¹ Department of Pediatric Hematology & Oncology Universitätsklinikum des Saarlandes Homburg Germany.
² Department of Hemostaseology and Transfusion Medicine Universitätsklinikum des Saarlandes Homburg Germany.

Abstract

We report the case of a Jehovah's Witness adolescent patient with immune-mediated thrombotic thrombocytopenic purpura after SARS-Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA). Further patients for whom TPE is not an option might benefit from this approach.

Keywords: Jehovah's Witness; caplacizumab; immune‐mediated TTP – SARS‐Cov2; immunoadsorption; therapy without therapeutic plasma exchange.

Publication types

Case Reports